Cell Reports (Jan 2023)

Protein adduction causes non-mutational inhibition of p53 tumor suppressor

  • Ravindran Caspa Gokulan,
  • Kodisundaram Paulrasu,
  • Jamal Azfar,
  • Wael El-Rifai,
  • Jianwen Que,
  • Olivier G. Boutaud,
  • Yuguang Ban,
  • Zhen Gao,
  • Monica Garcia Buitrago,
  • Sergey I. Dikalov,
  • Alexander I. Zaika

Journal volume & issue
Vol. 42, no. 1
p. 112024

Abstract

Read online

Summary: p53 is a key tumor suppressor that is frequently mutated in human tumors. In this study, we investigated how p53 is regulated in precancerous lesions prior to mutations in the p53 gene. Analyzing esophageal cells in conditions of genotoxic stress that promotes development of esophageal adenocarcinoma, we find that p53 protein is adducted with reactive isolevuglandins (isoLGs), products of lipid peroxidation. Modification of p53 protein with isoLGs diminishes its acetylation and binding to the promoters of p53 target genes causing modulation of p53-dependent transcription. It also leads to accumulation of adducted p53 protein in intracellular amyloid-like aggregates that can be inhibited by isoLG scavenger 2-HOBA in vitro and in vivo. Taken together, our studies reveal a posttranslational modification of p53 protein that causes molecular aggregation of p53 protein and its non-mutational inactivation in conditions of DNA damage that may play an important role in human tumorigenesis.

Keywords